公开(公告)号：US20210041428A1

公开(公告)日：2021-02-11

申请号：US17069591

申请日：2020-10-13

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Robert F. Zuk ,  Hong Tan ,  Qing Xia ,  Pu Li ,  Haode Chen ,  Heng Wu

IPC: G01N33/543 ,  G01N33/533 ,  G01N33/53 ,  G01N33/58

Abstract: The present invention is directed to methods for increasing sensitivities of immunoassays. The invention utilizes an acid elution condition that preferentially elute specifically bound immune complexes over non-specifically bound complexes from a solid phase, and designs immunoassay protocols that improve the ratio of specific binding to non-specific binding and thereby improving assay sensitivity. The protocol determines the signal of the labeled immunocomplexes eluted from a solid phase.

公开(公告)号：US20180180606A1

公开(公告)日：2018-06-28

申请号：US15903838

申请日：2018-02-23

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Robert F. Zuk ,  Hong Tan ,  Qing Xia ,  Pu Li ,  Haode Chen ,  Heng Wu

IPC: G01N33/543 ,  G01N33/533 ,  G01N33/53

CPC classification number: G01N33/54306 ,  G01N33/53 ,  G01N33/5306 ,  G01N33/533 ,  G01N33/543 ,  G01N33/582

Abstract: The present invention is directed to methods for increasing sensitivities of immunoassays. The invention utilizes an acid elution condition that preferentially elute specifically bound immune complexes over non-specifically bound complexes from a solid phase, and designs immunoassay protocols that improve the ratio of specific binding to non-specific binding and thereby improving assay sensitivity. The protocol determines the signal of the labeled immunocomplexes eluted from a solid phase.

公开(公告)号：US20250019780A1

公开(公告)日：2025-01-16

申请号：US18900261

申请日：2024-09-27

Applicant: Access Medical Systems, Ltd.

Inventor： Robert F. Zuk ,  Samuel Yang ,  Alex Ho Fai Lee ,  Indrani Chakraborty ,  Pu Li ,  Wai Choi

IPC: C12Q1/70 ,  G01N33/53 ,  G01N33/569 ,  G01N33/58

Abstract: The present invention is directed to a method of determining DNA concentration in a DNA virus. The invention features three basic steps. The initial step is the specific capture of a defined amount of virus capsid particles on a first solid phase. The second step is lysis of the capsid to release the virus DNA from the first solid phase into a lysis solution. After separating the lysis solution from the first solid phase, the third step is contacting the lysis solution with a second solid phase. The second solid phase captures total DNA derived from the captured capsid. The present invention is also directed to a method for measuring the percentage of full virus capsid, comprising first determining the ssDNA concentration in viruses, and then converting the ssDNA concentration to percentage of full virus capsid using a calibration curve having DNA concentration plotted against standards of % of full capsids.

公开(公告)号：US10809251B2

公开(公告)日：2020-10-20

申请号：US15903838

申请日：2018-02-23

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Robert F. Zuk ,  Hong Tan ,  Qing Xia ,  Pu Li ,  Haode Chen ,  Heng Wu

IPC: G01N33/543 ,  G01N33/533 ,  G01N33/53 ,  G01N33/58

Abstract: The present invention is directed to methods for increasing sensitivities of immunoassays. The invention utilizes an acid elution condition that preferentially elute specifically bound immune complexes over non-specifically bound complexes from a solid phase, and designs immunoassay protocols that improve the ratio of specific binding to non-specific binding and thereby improving assay sensitivity. The protocol determines the signal of the labeled immunocomplexes eluted from a solid phase.

公开(公告)号：US20240248084A1

公开(公告)日：2024-07-25

申请号：US18437032

申请日：2024-02-08

Applicant: ACCESS MEDICAL SYSTEMS, LTD.

Inventor： Robert F. Zuk ,  Pu Li ,  Vasundhra Bahl ,  Samuel Yang

IPC: G01N33/557 ,  G01N33/543

CPC classification number: G01N33/557 ,  G01N33/54306

Abstract: The present invention is directed to biochemical assay methods, which uses a biotin-immobilized solid support surface for quantitating an analyte or measuring kinetic binding in different samples, from about 3 to 20 times, while maintaining acceptable assay performance. The methods use a streptavidin capture solution comprising streptavidin or preferably streptavidin polymers. The biotin-immobilized solid support surface is regenerated after each cycle of reactions by contacting the surface in an acidic solution having pH about 1-4, followed by DMSO. The regeneration step removes the bound immunocomplex and leaves the biotin on the surface.